Zentalis Pharmaceuticals’ $165.2 Million Initial Public Offering

Latham advised Zentalis Pharmaceuticals on the deal. Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced the pricing of its initial public offering of 9,180,000 shares of common stock…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Ambrogio Visconti

This content is for Standard 1 Year members only.
Login Join Now